Market Snapshot: Under Pressure, Insulin Makers Pin Hopes On New Products
Bevy of new products like Novo Nordisk’s Tresiba offer some incremental improvements over older insulins, but in an increasingly crowded market, payers have the upper hand.
You may also be interested in...
UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.
The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.